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Purpose: The Nuclear Regulatory Commission deems it to be a medical event (ME) if the total
dose delivered differs from the prescribed dose by 20% or more. A dose-based definition of ME is
not appropriate for permanent prostate brachytherapy as it generates too many spurious MEs and
thereby creates unnecessary apprehension in patients, and ties up regulatory bodies and the
licensees in unnecessary and burdensome investigations. A more suitable definition of ME is
required for permanent prostate brachytherapy.
Methods and Materials: The American Society for Radiation Oncology (ASTRO) formed a
working group of experienced clinicians to review the literature, assess the validity of current
regulations, and make specific recommendations about the definition of an ME in permanent
prostate brachytherapy.
Results: The working group found that the current definition of ME in §35.3045 as “the total dose
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is dependent on the timing of the imaging, the imaging modality used, the observer variability in
prostate contouring, the planning margins used, inadequacies of brachytherapy treatment planning
systems to calculate tissue doses, and seed migration within and outside the prostate. If a dose-
based definition for permanent implants is applied strictly, many properly executed implants
would be improperly classified as an ME leading to a detrimental effect on brachytherapy. The
working group found that a source strength-based criterion, of N20% of source strength prescribed
in the post-procedure written directive being implanted outside the planning target volume is more
appropriate for defining ME in permanent prostate brachytherapy.
Conclusions: ASTRO recommends that the definition of ME for permanent prostate
brachytherapy should not be dose based but should be based upon the source strength (air-kerma
strength) administered.
© 2011 American Society for Radiation Oncology. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Introduction
Brachytherapy in the United States is regulated by the
Nuclear Regulatory Commission (NRC) under the Code
of Federal Regulations (CFR) 10 Part 35. Under Part 35
section §35.3045 it is deemed to be a medical event (ME)
(medical event was previously termed as “misadministra-
tion”) if “the total dose delivered differs from the
prescribed dose by 20 percent or more.” Such a rule is
not appropriate for permanent prostate brachytherapy
since, during the several weeks time interval between the
initial (preplan) volume study and the imaging performed
for dosimetry, there are several changes that occur in the
treatment volume (eg, the prostate gland) and the relative
position of the radioactive sources within the treatment
site which affect the final calculated dose. Further, the
prostate volume and therefore the resultant calculated
absorbed dose vary upon the imaging modality used,
observer variability in prostate contouring, and variability
in planning margins used among authorized users (AUs).
Due to the above factors, the final calculated dose may
vary from the planned dose by N20% even if an implant is
properly performed. If the NRC definition is rigidly
applied, many properly executed implants will be deemed
MEs, create unnecessary patient apprehension, and
encumber regulatory bodies and the licensees with
clinically irrelevant and costly investigations. Hence, a
dose-based definition of ME is not suitable for permanent
prostate brachytherapy. The American Society for Radia-
tion Oncology (ASTRO) therefore formed aworking group
to offer recommendations regarding the appropriate
definition of ME for permanent prostate brachytherapy.Methods
ASTRO formed a working group of experts in brachy-
therapy to formulate recommendations about the appropriate
definition of ME for permanent prostate brachytherapy. The
working group members, listed in the acknowledgment
section, are or have been leaders of professional radiationoncology and radiation physics organizations. They have
collectively performed and evaluated tens of thousands of
brachytherapy procedures and have published extensively
on various aspects of brachytherapy. The working group
reviewed the 2002 Code of Federal Regulations Part 35
sections on written directive (WD) in §35.40 and on ME in
§35.3045 and identified sections of the rules that were not
suitable for defining ME in permanent prostate implants.
They formulated specific recommendations for definingME
for permanent prostate brachytherapy by a review of the
pertinent literature and were guided by their clinical
experience and consensus opinion. Selected members of
the working group (the authors of this report) drafted the
report. This document was then reviewed by the ASTRO
prostate expert panel and posted on the ASTRO website to
secure public comments. The document was then revised to
reflect the consensus.Results
The working group found that the current definition of
ME in §35.3045 as the total dose delivered differs from the
prescribed dose by 20% or more was not suitable for
permanent prostate brachytherapy because the prostate
volume (and hence the resultant calculated prostate
absorbed dose) depends upon many factors including the
following: (a) the timing of the imaging; (b) the imaging
modality selected; (c) the observer variability in prostate
contouring; and (d) the planning margins used. Addition-
ally, the calculated dose could also vary due to seed
migration within and outside the prostate. This variation in
calculated dose exceeds 20% in prostate seed brachyther-
apy literature. Therefore, if the current dose-based ME
definition was strictly applied, many properly executed
implants would be improperly classified as an ME leading
to a detrimental effect on brachytherapy. The working
group recommends using a source strength-based rule.
Source strength relates to the activity implanted. Activity,
per se, poses a problem because, for the same activity
within a source the attenuation of the source components
produces different radiation fields for various source
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criterion of N20% of source strength prescribed in the post-
procedure written directive being implanted outside the
planning target volume for defining ME in permanent
prostate brachytherapy. The following sections detail the
rationale for the working group's recommendation.
Prostate gland volume changes relative to time
of implant
The shape and volume of the prostate gland can change
secondary to the effects of androgen ablative therapy,
postimplant edema, and variations in findings on different
imaging modalities. The prostate volume determined on
the initial volume study before the procedure and the
prostate volume after the procedure used for dose
calculation (also used to determine regulatory compliance)
may be significantly different.1,2 During the interval
between planning volume study and the brachytherapy
procedure, the prostate gland may shrink up to 33% when
androgen ablative therapy is used.3 During needle
insertion, the prostate gland typically swells (ie, the
prostate volume enlarges) from edema and hemorrhage
due to needle and seed insertion, typically reaching a
maximum volume within a few hours of procedure
completion. The edema and hemorrhage gradually resolve
over the next several weeks. The magnitude and time
course of this volume change are highly variable from
patient to patient and beyond the control of the AU. These
changes can be as high as 50% in some cases.1,2
Institutions vary widely on timing of postimplant
imaging. Some physicians obtain images for dosimetry
on the day of the implant (while there is still significant
edema) so they can evaluate the implant dosimetry
promptly, while others wait about 4 weeks with iodine-
125 (125I) seed implants to allow resolution of the edema.
Since the prostate volume may change markedly from the
day of implant to day 30, the resultant calculated doses
may vary in an individual patient by as much as 50%
depending on when the imaging was performed.
The implications of these volume changes are twofold.
First, to account for any volume changes occurring before
and during the implant procedure ME must be based on
the deviation from the WD completed after administra-
tion rather than the preimplant WD. Second, regulations
for ME cannot be based upon comparisons of planned
dose and calculated dose from postimplant images in
permanent implants.
The prostate volume varies based upon the
imaging modality used
Different imaging modalities (eg, magnetic resonance
imaging, computed tomography [CT], and ultrasound)
estimate prostate volumes differently for the same patient.4For example, CT can overestimate the prostate volume
by as much as 50% as compared with transrectal
ultrasound.5 If, as is usually the case, the preimplant
volume study and the implant are performed using
transrectal ultrasound images and the postimplant
dosimetry is calculated using CT images, the volume
differences will result in markedly different calculated
doses. Such differences may be perfectly acceptable
clinically but exceed the regulatory parameters if a dose-
based criterion is used to define ME.
Observer variability in prostate contouring
In order to calculate dose, the prostate is outlined
(contoured) on an image dataset. Different physicians
contour the prostate differently due to imaging limitations
and variability in image interpretation (acceptable vari-
ances in clinical judgment) that result from imaging
artifacts from the seeds and indistinct prostate boundaries
in postimplant CT images that are used for such
dosimetry calculations. These factors can lead to large
apparent differences in prostate volumes (interobserver
variability) and thus the calculated doses in a given
patient may vary considerably based upon interpretation
alone and not actual dose differences.6,7 In a study by Lee
et al,7 the mean prostate D90 (reported as percentage of
the dose to 90% of the prostate) on the very same patients,
varied from 75.1% to 102.6% (P b .0001) because 5
experienced reviewers interpreted the prostate volume
differently during target contouring. Thus, if a dose-based
criterion is used for a particular patient the implant could
be classified as an ME by some observers and clinically
suitable by others depending upon how the prostate was
contoured, although the actual dose delivered to the
prostate would be the same. There is even variability
(albeit less) when the same individual physician contours
a specific prostate image on different occasions
(ie, intraobserver variability over time).
Variability in treatment planning margins used
An AU often treats a variable margin of normal tissues
around the prostate gland to include possible microscopic
spread. This volume is termed the clinical target volume
(CTV). A margin is typically added around the prostate
CTV to create a planning target volume within which the
sources are distributed in order to ensure that the CTV is
adequately treated (Figure 1). Physicians reasonably vary
in how much margin they add around the prostate during
the treatment planning process. Some physicians adjust the
margin to account for possible edema and its resolution
while others do not. This variation in the planning margins
used can significantly affect the final calculated dose to
the prostate and also explains why sources can justifiably
be present outside the prostate gland.
GTV = gross tumor volume (usually the prostate). 
CTV = clinical target volume which includes a variable margin of normal tissues.
around the prostate gland to include possible microscopic spread.
PTV = planning target volume – includes a margin within which the sources are 








Figure 1 Expansion margins in prostate brachytherapy.
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There are 2 types of seed migration in prostate
brachytherapy procedures. (1) Some seeds could be
deposited into the periprostatic blood vessels and then
travel intravascularly to distant organs like the lung. This
event is correctly recognized not to be ME by the NRC,
which excludes sources that were implanted in the correct
site but migrated outside the treatment site from ME
definition. (2) There is a second method of seed migration
which could trigger an ME if a rigid definition of ME is
used. In this second method, some of the deposited seeds
could migrate within and just outside the prostate during
the radiation delivery. The effects of this second form of
migration would lead to an alteration of the calculated
prostate dose and thereby could trigger a spurious ME.8
Historical method of prescription for
permanent brachytherapy
At its inception, the prescription of permanent prostate
brachytherapy was defined in terms of apparent activity
(in mCi) and has now been redefined in terms of source
strength in air-kerma strength (U). For 125I, the apparent
activity (in mCi) to be implanted was initially given by
the formula (5 × the average dimension of the tumor),
which evolved into more complex nomograms with the
activity based on the volume to be implanted for a desired
peripheral dose. In the last 2 decades, due to the advent of
CT scanning and 3-dimensional dosimetry, it has become
possible to estimate the delivered dose. Several dosimet-ric parameters such as D100, D90, and D80 (ie, dose to
100%, 90%, and 80% of the prostate gland, respectively),
and V100, V150, and V200 (ie, the percentage of prostate
volume receiving 100%, 150%, and 200% of the
prescribed dose, respectively) have been formulated to
make clinical outcome comparisons.1,9-11 These dosimet-
ric parameters may be of prognostic significance but they
were not designed for, nor are they suitable for,
regulatory compliance.Working group recommendation
Section 35.40 allows the WD to be prescribed in terms
of the total dose or be prescribed in terms of the total
source strength and exposure time. For permanent
implants the qexposure timeq is infinite, hence the WD
would be the total source strength. As noted in sections 1
through 6 above, the total source strength implanted into
the target volume is under control of the AU, but the
subsequent prostate volume and the resultant dose to the
prostate is not. The actual dose and the dosimetric
parameters vary considerably depending upon when and
how the images were obtained and how the prostate was
contoured. Hence, a dose-based criterion for ME is not
suitable for permanent prostate brachytherapy. On the
other hand, a source strength-based criterion of N20% of
source strength prescribed in the post-procedure written
directive being implanted outside the planning target
volume will correctly identify as ME cases in which a large
number of sources have been improperly implanted
outside the treatment site, but be less likely to generate
spurious ME than a dose-based definition. Hence, ASTRO
recommends using the implanted source strength-based
metric to define ME in permanent prostate brachytherapy.
The working group recognized one scenario where an
implanted source strength metric does not adequately
identify an ME. It is when all or most of the sources are
erroneously implanted within a small region of the target
volume, leaving a substantial portion of the treatment site
uncovered. Under this circumstance some of the target will
be overdosed and other areas under dosed. This theoretical
possibility is rarely observed in clinical practice. However,
to address this scenario, ASTRO recommends that the AU
be required to affirm in writing on the WD, after the
implant is completed, that the distribution of the sources
within the treatment site was as intended per the WD.
Illustrative case examples
The following diagrammatic representation (Figure 2)
illustrates volumetric and dose changes that occur after
prostate brachytherapy that may lead to an inappropriate
classification as an ME. The preimplant WD for a patient
was for 38 U (or 30 mCi apparent activity) in total, to




Vol. = 32 cm3
Postplan:
38 U; 
89 Gy (62 %);
Vol. = 63 cm3
Figure 2 Apparent under dose due to volume change which




volume = 23 cm3
Postplan:
39 U; but 17 U (43%)
outside prostate;
99 Gy (62 %);
volume = 19 cm3
Figure 3 Under dose and medical event due to incorrect
seed placement.
222 S. Nag et al Practical Radiation Oncology: October-December 2011The seeds were implanted according to the treatment
plan. The postimplant CT-based dosimetry, however,
revealed D90 dose of 89 Gy (62 % of the original planned
dose) because the prostate volume had swelled to 63 cm3
at the time of the CT evaluation. The patient's disease
was well controlled with no untoward effects. This
implant would be deemed an ME if a dose-based rule is
used, but it is correctly categorized not to be an ME if
implanted source strength-based metric is used. Under
the dose-based rule, the AU would have had to notify the
patient that an ME had occurred, potentially causing
unnecessary apprehension and distress to the patient who
may have taken additional unnecessary treatments, which
would have been poor clinical medical practice as well as
poor regulatory policy. Note that if the CT scan had been
taken at a different time interval when the edema had
resolved and the prostate volume had shrunk close to its
original volume, the resultant dose would have more
closely approximated that in the WD. Using an implanted
source strength-based metric to determine regulatory
compliance would have noted that all of the sources were
located within the treatment site regardless of the prostate
volume change and therefore would not have classified it
as an ME.
The above example contrasts with another case where
the sources were improperly implanted with the seeds
being displaced relative to the treatment site (Figure 3).
The WD was for 39 U (or 31 mCi), 160 Gy for a prostate
volume of 23 cm3. The postimplant CT scan showed that
the D90 was 99 Gy (62 %) for a prostate volume of 19 cm3
but that 17 U (13 mCi) (43%) of implanted source strength
was outside the treatment site. This error in the implant
process resulted in a dose lower than the goal, which is
correctly classified as an ME using the implanted source
strength-based criteria.Discussion
ASTRO is very much concerned that if the current
dose-based definition for an ME is strictly applied forpermanent seed brachytherapy, many properly executed
medically acceptable implants will erroneously be labeled
as MEs. It is difficult to accurately predict exactly how
many implants in this country will be mislabeled as ME
using the dose-based rules. However, if all the factors
noted here are added it is estimated that at least 10%-25%
of all permanent prostate seed implants done in the
United States (ie, thousands of implants per year) could
be considered as MEs, depending on how strictly the
rules are applied and interpreted and how extensively a
brachytherapy center is audited. Such a situation would
be harmful to the public welfare as it will create undue
apprehension in patients and the general public and likely
occupy the NRC, state regulatory bodies, and the
licensees in thousands of man-hours of unnecessary and
clinically irrelevant costly investigations.
This outcome was unfortunately demonstrated in a
recent Veterans Affairs Hospital (VAH) audit in which an
unacceptable number of permanent prostate implant
brachytherapy (97 out of 116 prostate cancer treatment
procedures) were deemed as MEs using the existing dose-
based ME criterion.12 However, on reanalysis, 80 of these
97 were actually not considered MEs using an implanted
source strength-based metric recommended by the “VAH
blue ribbon panel” or the Advisory Committee for the
Medical Use of Isotopes and the scientific organizations
including ASTRO because many of these apparent MEs
were due to prostate volume changes.12 It should be noted
that the implanted source strength-based ME criteria
would still correctly identify the 17 medically unaccept-
able implants as MEs.
Another concern of ASTRO is that there is the very
real risk that, as a result of these inappropriate rules,
some practitioners will abandon permanent seed brachy-
therapy and thus access to this effective treatment
modality could be impaired. We urge the NRC to heed
the ASTRO recommendations to achieve an optimal
balance between high sensitivity and high specificity in
determining MEs for public safety while maintaining
patient access and good clinical outcomes in permanent
prostate brachytherapy.
Medical event definition for brachytherapy 223Practical Radiation Oncology: October-December 2011Conclusions
ASTRO recommends that the definition of ME for
permanent prostate brachytherapy should be based on
the implanted source strength (N20% of source strength
prescribed in the post-procedure written directive being
implanted outside the planning target volume) and not
be dose based. If a dose-based definition for permanent
prostate implants is applied strictly many medically
acceptable implants would be inappropriately classified
as an ME, and rather than achieving the intended
goal of patient safety there will be a detrimental effect
on brachytherapy.Acknowledgments
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